613 related articles for article (PubMed ID: 12826530)
1. Epidemiology of inhibitors and current treatment strategies.
Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
[TBL] [Abstract][Full Text] [Related]
2. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
3. The role of VWF for the success of immune tolerance induction.
Kreuz W
Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
[TBL] [Abstract][Full Text] [Related]
4. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
5. Immune tolerance induction in patients with hemophilia A.
Astermark J
Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
[TBL] [Abstract][Full Text] [Related]
6. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
Gringeri A
Haemophilia; 2007 Dec; 13 Suppl 5():73-7. PubMed ID: 18078402
[TBL] [Abstract][Full Text] [Related]
7. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
Franchini M; Lippi G
Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
10. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
[TBL] [Abstract][Full Text] [Related]
12. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
13. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
14. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
Berntorp E
Haematologica; 2003 Jun; 88(6):EREP03. PubMed ID: 12826529
[TBL] [Abstract][Full Text] [Related]
15. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
16. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
18. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
Oldenburg J; Austin SK; Kessler CM
Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
[TBL] [Abstract][Full Text] [Related]
19. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
[TBL] [Abstract][Full Text] [Related]
20. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]